IC31® and IC30, novel types of vaccine adjuvant based on peptide delivery systems

Expert Review of Vaccines

Volumn 6, Issue 5, 2007, Pages 741-746

  Lingnau, Karen ^a   Riedl, Karin ^a   Von Gabain, Alexander ^a  

^a INTERCELL AG   (Austria)

Author keywords

Adjuvant; Antibody; Protection; T cell; Toll like receptor; Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS C ANTIGEN IC 30 VACCINE; IC 30; IC 31; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INFLUENZA ANTIGEN IC 31 VACCINE; OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE 1A; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PHOSPHORYL LIPID A; POLYARGININE; POLYPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN DERIVATIVE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUBERCULOSIS ANTIGEN IC 31 VACCINE; UNCLASSIFIED DRUG; SUBUNIT VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINE PRODUCTION; ANIMAL; ANTIBODY PRODUCTION; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; DRUG DELIVERY SYSTEMS; HUMANS; VACCINES, SUBUNIT;

EID: 35348988624     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.5.741     Document Type: Review

References (24)

1. Gearing AJ. Targeting Toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell Biol. 85(6), 490-494 (2007). • Commercial approaches to develop new Toll-like receptor drugs.
2. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
3. Wagner E, Zenke M, Cotton M, Beug H, Birnstiel ML. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl Acad. Sci. USA 94, 3262-3267 (1990).
4. Shen WC, Ryser HJ. Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. Proc. Natl Acad. Sci. USA 75, 1872-1876 (1978).
5. Shen WC, Ryser HJ. Poly(L-lysine) has different membrane transport and drug carrier properties when complexed with heparin. Proc. Natl Acad. Sci. USA 78, 7589-7593 (1981).
6. Buschle M, Schmidt W, Zauner W et al. Transloading of tumor antigen-derived peptides into antigen presenting cells. Proc. Natl Acad. Sci. USA 94, 3256-3261 (1997).
7. Mattner F, Fleitmann JK, Lingnau K et al. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long lasting T cell responses against cancer antigens. Cancer Res. 62, 1477-1480 (2002). •• Demonstrates the adjuvant effects of IC30.
8. 5KLK (KLK).
9. Uematsu S, Akira S. Toll-like receptors and innate immunity. J. Mol. Med. 84, 712-725 (2006).
10. Lingnau K, Egyed A, Schellack C, Mattner F, Buschle M, Schmidt W. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20, 3498-3508 (2002).
11. Schijns VEJC. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune response by vaccine adjuvants. Vaccine 21, 829-831 (2003). • Reviews the most important concepts explaining mechanisms of vaccine adjuvant activity.
12. Schellack C, Prinz K, Egyed A et al. IC31, a novel adjuvant signaling via TLR9, inducespotent cellular and humoral immune responses. Vaccine 24, 5461-5472 (2006). •• Demonstrates the adjuvant effects of IC31® and its mechanisms of action.
13. Yasuda K, Rutz M, Schlatter B et al. CpG motif-independent activation of TLR9 upon endosomal translocation of 'natural' phosphodiester DNA. Eur. J. Imunol. 36, 431-436 (2006).
14. Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24, 5452-5460 (2006). • Demonstrates IC31 as a potent adjuvant for tuberculosis.
15. Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 186, 2063-2068 (1997).
16. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177, 2888-2898 (2006).
17. Wareing MD, Tannock GA. Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57. Vaccine 21, 3097-3100 (2003).
18. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese M. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol. Rev. 159, 95-103 (1997).
19. + T cells in healthy individuals and chronic hepatitis C patients. Vaccine 25(37-38), 6793-6806 (2007). • Clinical results with the IC30-adjuvanted therapeutic HCV vaccine.
20. Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized , placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24, 4343-4353 (2006). • Clinical results with the IC30-adjuvanted therapeutic HCV vaccine.
21. Anderson P. Subunit vaccines against tuberculosis. Presented at: Keystone Symposia - Tuberculosis: From Lab Research to Field Trials. Vancouver, Canada, 20-25 March 2007. •• Conference talk on the first clinical data with the IC31-adjuvanted tuberculosis vaccine.
22. Ottenhoff T. Results from a first clinical safety and immunogenicity Phase 1 trial with a new subunit vaccine against tuberculosis. Presented at: Semmering Conference - Challenges for Vaccine Development: Medical Needs and Social Implications. Baden, Austria, 12-15 April 2007. •• Conference talk on the first clinical data with the IC31-adjuvanted tuberculosis vaccine.
23. EMEA www.emea.europa.eu
24. US FDA www.fda.gov